Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07622667

Correlation Analysis of Gene Characteristics of Malignant Tumors With Prognosis

This study is a single-center observational investigation aimed at systematically exploring the key molecular features influencing the prognosis of malignant tumors by integrating multidimensional clinical information with multi-omics molecular data. The goal is to provide a critical scientific basis for constructing precise prognostic prediction models, identifying potential therapeutic targets, and optimizing clinical treatment strategies. The study plans to consecutively enroll adult patients with histologically confirmed malignant tumors who received antitumor therapy at our hospital between January 2017 and December 2025. Clinical data (including demographic characteristics, tumor pathology information, treatment histories, and survival follow-up data) will be systematically collected from electronic medical records. Additionally, tumor tissue or blood samples will be obtained from the patients for sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry analysis to comprehensively characterize the genomic features, immune microenvironment, and cellular heterogeneity of the tumors.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Malignant Tumors Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, China

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Voluntarily sign the informed consent form.
  • Treated at Nanfang Hospital, Southern Medical University between January 2017 and December 2025.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
  • Availability of surplus routinely discarded clinical tumor tissue samples (biopsy specimens or pathological sections) or blood samples for assays such as sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry.

Exclusion criteria

Patients deemed by the investigator to be unsuitable for participation in this study.

Treatment and study plan

Immunotherapy Therapy

Drug

Patients receiving immunotherapies such as immune checkpoint inhibitors. Immunotherapy can be administered as first-line or subsequent treatment, or as part of combination therapy, integrated with modalities such as surgery, chemotherapy, radiotherapy, and targeted therapy.

radiation therapy

Radiation

Patients for whom radiotherapy is the primary or a significant component of their treatment. Radiotherapy may be administered with curative, adjuvant, or palliative intent, and can be given alone or in combination with surgery, chemotherapy, targeted therapy, immunotherapy, etc.

Radical surgery

Procedure

Patients undergoing curative tumor resection as their primary treatment modality. Surgery may be performed with or without neoadjuvant/adjuvant chemotherapy, radiotherapy, targeted therapy, or immunotherapy.

Primary outcomes

  1. Overall Survival (OS)

    Time frame: From date of treatment initiation until date of death or last follow-up, assessed up to 5 years.

    The time from the start of treatment to death from any cause. Patients who are alive at the last follow-up are censored.

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Time frame: From date of treatment initiation until date of progression or death, assessed up to 5 years.

    The time from the start of treatment to the first documented disease progression (per RECIST criteria) or death from any cause, whichever occurs first.

  2. Pathological Complete Response (pCR)

    Time frame: At the time of surgery following neoadjuvant treatment, typically within 4-6 weeks after completion of therapy.

    The absence of residual invasive cancer in the resected tumor specimen and lymph nodes after neoadjuvant therapy, as determined by histopathological evaluation.

  3. Major Pathologic Response (MRP)

    Time frame: At the time of surgery following neoadjuvant treatment, typically within 4-6 weeks after completion of therapy.

    The presence of ≤10% residual viable tumor cells in the resected tumor specimen after neoadjuvant therapy, assessed by pathological examination.

Study contacts

Contact information is provided by the study sponsor or research team.

Wei Wang Wang

CONTACT

[email protected]

02061642135

Sponsors and collaborators

Lead sponsor

Nanfang Hospital, Southern Medical University

Other

Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jun 3, 2026
Registry last updated
Jun 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.